KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Free Cash Flow (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Free Cash Flow data on record, last reported at $22.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 51.91% year-over-year to $22.0 million; the TTM value through Dec 2025 reached $75.7 million, up 140.63%, while the annual FY2025 figure was $75.7 million, 140.67% up from the prior year.
  • Free Cash Flow reached $22.0 million in Q4 2025 per RIGL's latest filing, down from $24.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $54.8 million in Q2 2021 and bottomed at -$25.9 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $1.6 million, with a median of -$2.7 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: crashed 441.24% in 2021, then soared 10011.59% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$19.1 million in 2021, then dropped by 15.3% to -$22.0 million in 2022, then soared by 71.61% to -$6.2 million in 2023, then soared by 332.0% to $14.5 million in 2024, then surged by 51.91% to $22.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $22.0 million in Q4 2025, $24.0 million in Q3 2025, and $30.5 million in Q2 2025.